Avista Pharma Acquires Solid Form Solutions

Published on: 

Avista Pharma's strengthens early phase drug development offerings with acquisition of Solid Form Solutions.

Avista Pharma Solutions expanded its solid-phase chemistry services with the acquisition of Solid Form Solutions on Jan. 23, 2018, adding solid state chemistry and crystallization development services for the pharmaceutical industry.

The company now offers a suite of drug development services ranging from analytical development to API and drug product manufacturing, according to a Jan. 23, 2018 statement announcing the completion of the acquisition.

Solid Form Solutions will continue operating in its Edinburgh, Scotland facility, providing salt screening and selection services, co-crystal and polymorph screening, crystallization development, and other analytical testing and development.


In 2017, Avista Pharma announced the expansion of analytical research and development capabilities in Durham, NC; API and drug product manufacturing capacity in Longmont, CO; and microbiology and sterility testing capabilities in Agawam, MA.

Source: Avista Pharma Solutions